Molecular Partners

Allergan, Molecular Partners form two exclusive alliances in eye disease

Tuesday, August 21, 2012

Allergan, a multi-specialty health care company based in Medford, Mass., and Molecular Partners, a privately-owned Swiss biotech focused on a class of biological drugs known as DARPins, have significantly expanded their existing relationship by entering into two separate agreements to discover, develop and commercialize proprietary therapeutic DARPin products for the treatment of serious ophthalmic diseases.

[Read More]

Molecular Partners expands research collaboration with Janssen Biotech

Thursday, December 8, 2011

Molecular Partners has entered into a strategic research collaboration and option agreement with Janssen Biotech to research, discover and develop DARPin products for the treatment of immunological diseases. The collaboration and expansion of its current agreement with the company and its affiliates aims to explore a defined set of targets, including the use of multispecific DARPins, to address diseases where continued unmet needs for effective treatment options continue to exist.

[Read More]